In large clinical trials conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support—such as the need for mechanical ventilation. A trend in possible reduction of mortality was also observed and is being further studied. With...
Regional hospital protocols to expedite emergency care for major heart attacks benefit some communities more than others, according to a retrospective review of California residents.
For more than a decade, NHLBI’s Learn More Breathe Better SM program has worked with leading lung health organizations around the country to educate, engage, and empower the more than 16 million Americans living with chronic obstructive pulmonary disease (COPD), as well as their families, caregivers, and health care providers. As the nation marks...
Dos líderes de los NIH llaman a sus comunidades a buscar de información verídica de fuentes confiables y promover la confianza en la ciencia para acabar con la COVID-19.
As the toll of illness and death from COVID-19 keeps rising across the country and continues to disproportionately affect racial and ethnic minorities, two NIH leaders are calling on their communities to get the facts and help build trust in science to turn the tide of the pandemic.
Using a life support machine to replicate the functions of the heart and lungs significantly improved the survival of people who suffered from out-of-hospital cardiac arrest, according to a new study published today in The Lancet . The treatment program involving the life support machine called extracorporeal membrane oxygenation (ECMO) proved so...
A study finds a 10-year prediction model for atherosclerosis, a hardening of the arteries, works well for most patients but may overestimate risks for patients with moderate to severe obesity.
Compared to a placebo, hydroxychloroquine, a common prescription medication to treat malaria and rheumatic conditions, neither causes harm nor provides any clinical benefit to hospitalized adults with COVID-19.
A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was...